-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, many "rookies" of innovative drug research and development have emerged in China, and a large number of "post-00s" new drug research and development enterprises have emerged!
The policy has played a set of "combination punches" in the fields of research and development, production, circulation, payment, capital, and supervision
R&D, production, circulation, payment, capital, and supervision either accelerate innovation or make profits for innovati.
"Post-00s" innovative pharmaceutical companies enter the market
The domestic technology-driven development strategy and the improvement of the business environment have spawned a large number of rising stars, and these "post-00s" companies are also competing on the road to I.
Among them, there are many Biotech companies that have achieved "A+H" listing in two places (such as Rongchang Biotechnology, Junshi Biotechnology), and even "A+H+N" listing in three places (such as BeiGen.
According to the public information of the Securities Times , a total of 19 innovative drug companies have successfully landed in the Hong Kong stock market and A-share market in 202 The number of innovative drug companies landing in the capital market is the highest in history, and this record is expected to be refreshed in 202
In 2021, a total of 19 innovative drug companies have successfully landed in the Hong Kong stock market and A-share mark.These pharmaceutical companies have been trying to break free from the "Me Too" circle from the very beginning and are committed to "Me Better", even "BIC" and "FI.
A rising star that stands out
Among these rising stars, many companies stand out, and can compete with Hengrui, the “first brother” of innovation in China, which is over 500 years old, and even foreign century-old pharmaceutical companies in popular emerging fiel.
It can compete with Hengrui, the “first brother” of innovation in China, which is over 500 years old, and even foreign century-old pharmaceutical companies in popular emerging fiel.
The broad-spectrum anticancer drug PD-1 has almost become synonymous with "involutio.
Another turbulent track that is not related to the new coronavirus is in the field of gene therapy, and in the field of ADC drugs,
Table 2: Performance of some "post-00" innovative drug companies in the past three years
I have to sigh with emotion: Father Xuan can still be afraid of future generations, but his husband can't be you.
Through comparative analysis, these outstanding pharmaceutical companies generally have several characteristics: attach importance to R&D investment, seize market opportunities, attach importance to overseas layout, and consolidate the advantages of the tra.
Where is the future?
Compared with the international pharmaceutical industry, we are learning from developed countries such as Japan, Europe and the United States: our Chinese pharmaceutical industry is currently undergoing a series of transformation and upgrading reforms such as review, cost control, price reduction, centralized procurement, DRG, and innovati.
Compared with the international pharmaceutical industry, we are learning from developed countries such as Japan, Europe and the United States:
About "new": In terms of the definition of "new", innovative pharmaceutical companies need to understand that new is not something new, and pharmaceutical companies need to always be based on clinical value-oriented innovati.
About "new": in the definition of "new", in the speed of "new", in the method of realizing "new", can we use new technology to develop new varieties and open up new markets!
Regarding internationalization: innovative pharmaceutical companies must always have a forward-looking layout logic based on the local area and facing the international mark.
Regarding internationalization: innovative pharmaceutical companies must always have a forward-looking layout logic based on the local area and facing the international mark.
About the cycle: "Ten years, one billion dollars" has become the second name of innovative dru.
About capital: The game of value measurement is what the capital side is most keen to do, but it is not the best at doing .
"There will be times when the wind and waves break, and the sails will be hung straight to help the sea"! By taking multiple measures, both internal and external, Chinese innovative pharmaceutical companies must make drugs that can withstand the test of policy, capital, manpower, clinical and market in the future!
